Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.

For older patients with EGFR-mutant advanced NSCLC, EGFR tyrosine kinase inhibitors are the most important treatment. Survival benefit of chemotherapy after failure of gefitinib seems limited.